A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis.
Fatigue occurs in a majority of patients with MS and is generally independent of measurable neurologic disability. Few options for treatment are available. We conducted a double-blind, placebo-controlled, crossover trial for each of two 4-week treatment periods. Forty-six eligible patients entered a...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1992
|
| _version_ | 1797092679929036800 |
|---|---|
| author | Weinshenker, BG Penman, M Bass, B Ebers, G Rice, G |
| author_facet | Weinshenker, BG Penman, M Bass, B Ebers, G Rice, G |
| author_sort | Weinshenker, BG |
| collection | OXFORD |
| description | Fatigue occurs in a majority of patients with MS and is generally independent of measurable neurologic disability. Few options for treatment are available. We conducted a double-blind, placebo-controlled, crossover trial for each of two 4-week treatment periods. Forty-six eligible patients entered and five dropped out due to concurrent exacerbations. Nineteen patients (46.3%) experienced excellent or good relief of fatigue with pemoline, and eight patients (19.5%) with placebo (p = 0.06, Fisher's exact test). One-fourth of patients did not tolerate the drug well, and 7% had to discontinue pemoline during the study due to side effects. The most common side effects were anorexia, irritability, and insomnia. Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients. |
| first_indexed | 2024-03-07T03:49:29Z |
| format | Journal article |
| id | oxford-uuid:c0b49081-30c9-4563-8a9b-a57e40111fe9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:49:29Z |
| publishDate | 1992 |
| record_format | dspace |
| spelling | oxford-uuid:c0b49081-30c9-4563-8a9b-a57e40111fe92022-03-27T05:56:25ZA double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c0b49081-30c9-4563-8a9b-a57e40111fe9EnglishSymplectic Elements at Oxford1992Weinshenker, BGPenman, MBass, BEbers, GRice, GFatigue occurs in a majority of patients with MS and is generally independent of measurable neurologic disability. Few options for treatment are available. We conducted a double-blind, placebo-controlled, crossover trial for each of two 4-week treatment periods. Forty-six eligible patients entered and five dropped out due to concurrent exacerbations. Nineteen patients (46.3%) experienced excellent or good relief of fatigue with pemoline, and eight patients (19.5%) with placebo (p = 0.06, Fisher's exact test). One-fourth of patients did not tolerate the drug well, and 7% had to discontinue pemoline during the study due to side effects. The most common side effects were anorexia, irritability, and insomnia. Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients. |
| spellingShingle | Weinshenker, BG Penman, M Bass, B Ebers, G Rice, G A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. |
| title | A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. |
| title_full | A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. |
| title_fullStr | A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. |
| title_full_unstemmed | A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. |
| title_short | A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. |
| title_sort | double blind randomized crossover trial of pemoline in fatigue associated with multiple sclerosis |
| work_keys_str_mv | AT weinshenkerbg adoubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT penmanm adoubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT bassb adoubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT ebersg adoubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT riceg adoubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT weinshenkerbg doubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT penmanm doubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT bassb doubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT ebersg doubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis AT riceg doubleblindrandomizedcrossovertrialofpemolineinfatigueassociatedwithmultiplesclerosis |